Welcome, Allan DeBono!

We are pleased to announce the arrival of Allan DeBono, who joins us in the role of Licensing and Commercialization Professional, supporting the commercialization of Princess Margaret (PM) Cancer Centre’s extensive research portfolio.

Allan is a cell and molecular biologist with a Ph.D. from the University of British Columbia (UBC) with strong experience in industry as a synthetic biologist. Allan earned an MBA at the UBC Sauder School of Business and developed an interest in consulting and venture development. He was recently the Health Diagnostics Stream lead at the Creative Destruction Lab(link is external) (CDL), an early stage science accelerator based at the University of Toronto Rotman School of Business, yet spanning an international footprint. His work at CDL focused on advancing human health innovations, including medical devices, to market.

Allan has worked in various biotechnology roles, business consulting and venture development, and is looking forward to pairing his career experiences with his deep knowledge of biology to advance the ripe oncology portfolio at the Princess Margaret Cancer Centre. Working alongside the PM commercialization team, Allan will support PM researchers and clinicians advance research and innovation with commercial applicability to the next level through expert evaluation, IP protection, marketing, licensing, and new company creation.

Allan is drawn to UHN for the opportunity to work with our world-leading researchers, excited by the potential of work that continually improves current standards of care and to advance discoveries that can better the lives of patients around the world.

Please join us in welcoming Allan!

‍